678 results on '"Vucinic, Vladan"'
Search Results
2. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
3. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
4. Web-Based Cognitive-Behavioral Therapy to Reduce Severe Cancer-Related Fatigue Among Survivors of Hodgkin Lymphoma: A Feasibility Study
5. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (CAR) T Cell Treatment for Relapsed/Refractory Multiple Myeloma
6. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial
7. Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study
8. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study
9. Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
10. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
11. A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
12. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
13. Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
14. A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.
15. Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
16. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
17. Results of a multicenter phase I/II trial of TCRαβ and CD19-depleted haploidentical hematopoietic stem cell transplantation for adult and pediatric patients
18. Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis
19. Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
20. Evaluation of Anti-CAR Linker mAbs for CAR T Monitoring after BiTEs/bsAbs and CAR T-Cell Pretreatment.
21. Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15
22. ATMP: der Weg in die Klinik
23. Prevalence of hypersensitivity reactions in various forms of mastocytosis: A pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry
24. Quantifying NPM1 MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
25. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
26. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
27. Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group
28. Scoring the Risk of Having Systemic Mastocytosis in Adult Patients with Mastocytosis in the Skin
29. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation
30. Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients
31. Impact of Previous Allogeneic Hematopoietic Stem Cell Transplantation on Chimeric Antigen Receptor (Car) T Cell Treatment for Relapsed/Refractory Multiple Myeloma
32. Bendamustine, prednisone and bortezomib (BPV) induction therapy prior autologous stem cell transplantation (ASCT) in 135 newly diagnosed multiple myeloma patients: comparison between patients with normal and impaired renal function
33. Biotechnologische Innovationen im Bereich zellulärer Therapien: CAR-T-Zellen als Beispiel für lebende Medikamente
34. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia
35. Pretreatment CD34+/CD38– Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation
36. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy
37. Management of Patients Undergoing CAR-T Cell Therapy in Germany.
38. Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
39. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation
40. Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
41. Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
42. Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
43. MDS-337 HeMonitor: Machine Learning-Based Noninvasive Estimation of Hemoglobin (Hb) Value in Patients With Hematological Malignancies
44. POSTER: MDS-337 HeMonitor: Machine Learning-Based Noninvasive Estimation of Hemoglobin (Hb) Value in Patients With Hematological Malignancies
45. OA-04 Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
46. P-009 Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma
47. Case report: Allogeneic stem cell transplantation for type B insulin resistance
48. CAR T cell therapy in multiple myeloma, where are we now and where are we heading for?
49. P352: PROPHYLACTIC AND PREEMPTIVE USE OF DLI COMPARE FAVOURABLY TO THEIR THERAPEUTIC USE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) – RESULTS OF A MULTICENTRE RETROSPECTIVE STUDY
50. P1315: THE CHRONOLOGICAL SEQUENCE OF 12 GY TOTAL BODY IRRADIATION AND CYCLOPHOSPHAMIDE CONDITIONING DOES NOT IMPACT OUTCOMES IN AML PATIENTS UNDERGOING MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.